BIOMAT Database Logo BIOMAT Database Logo

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD. 2022

William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. wbfeldman@bwh.harvard.edu.

UI MeSH Term Description Entries
D009330 Nebulizers and Vaporizers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments. Atomizers,Inhalation Devices,Inhalators,Inhalers,Vaporizers,Nebulizers,Vaporizers and Nebulizers,Atomizer,Device, Inhalation,Devices, Inhalation,Inhalation Device,Inhalator,Inhaler,Nebulizer,Vaporizer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D029424 Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA. Airflow Obstruction, Chronic,COAD,COPD,Chronic Airflow Obstruction,Chronic Obstructive Airway Disease,Chronic Obstructive Lung Disease,Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Diseases,Airflow Obstructions, Chronic,Chronic Airflow Obstructions

Related Publications

William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Market exclusivity for biologics.
February 2010, The New England journal of medicine,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Market exclusivity for biologics.
February 2010, The New England journal of medicine,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Brand name changes help health care providers win market recognition.
January 1993, Health marketing quarterly,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand.
August 1996, Chest,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Brand biologics grab 12 years' exclusivity, for now.
August 2009, Nature biotechnology,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Adalimumab pricing and market exclusivity for biologics.
December 2010, The New England journal of medicine,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Turbuhaler or nebulizer therapy in severe COPD.
January 1995, Respiratory medicine,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Substitution for Brand-Name Drugs.
May 1963, Canadian Medical Association journal,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Principles of nebulizer-delivered drug therapy for asthma.
September 1989, American journal of hospital pharmacy,
William B Feldman, and Doni Bloomfield, and Reed F Beall, and Aaron S Kesselheim
Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
May 2009, Health economics,
Copied contents to your clipboard!